Alkem Laboratories

Alkem Laboratories Financial Leverage

The Financial Leverage (Equity Multiplier) of Alkem Laboratories (ALKEM.NS) as of Nov 10, 2026 is 1.51. In the previous year, Financial Leverage (Equity Multiplier) was 1.48 — a change of 2.32% (higher).

Financial Leverage

1.51

YoY

2.32%

Last updated:

Financial Leverage (Equity Multiplier) of Alkem Laboratories is 2026 1.51 . Financial Leverage (Equity Multiplier) of Alkem Laboratories was 2025 1.48 . It decreases by 2.32% higher compared to the previous year.

The Alkem Laboratories Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.51 INR
Jan 1, 2020
1.61 INR
Jan 1, 2021
1.56 INR
Jan 1, 2022
1.63 INR
Jan 1, 2023
1.52 INR
Jan 1, 2024
1.51 INR
Jan 1, 2025
1.48 INR
Jan 1, 2026
1.51 INR
The Alkem Laboratories Financial Leverage history
YEARFinancial LeverageYoY
1.51+2.32%
1.48-2.27%
1.51-0.69%
1.52-6.63%
1.63+4.30%
1.56-3.27%
1.61+6.98%
1.51-4.25%
1.58+7.21%
1.47-1.93%
1.50-15.10%
1.77+7.84%
1.64—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alkem Laboratories stock

Financial Leverage (Equity Multiplier) of Alkem Laboratories is 1.51 in 2026.

Financial Leverage (Equity Multiplier) of Alkem Laboratories changed from 1.48 to 1.51, representing a 2.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Alkem Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Alkem Laboratories

All Key Metrics — Alkem Laboratories